Naurex Inc. Overview
Pro stress-test →Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system. In July 2015, Allergan acquired Naurex in an all-cash transaction, which has since become part of AbbVie's portfolio. The company was founded as a Northwestern University spinout focused on rapid-acting antidepressant therapies with a differentiated mechanism of action.
Strategic Profile
Pro stress-test →Naurex built a platform for discovering drugs that enhance synaptic plasticity through a novel mechanism that modulates the NMDA receptor, resulting in drugs that are both highly effective and well-tolerated. The lead candidate, rapastinel (GLYX-13), demonstrated rapid, substantial, and sustained antidepressant activity in Phase 2 studies without psychosis-like side effects.
Competitive Landscape
Pro stress-test →Naurex competed in the antidepressant therapeutics market against established treatments and emerging competitors developing novel mechanisms for depression. The company's differentiated NMDA modulation approach with rapid onset and tolerability profile positioned it as an innovative alternative to traditional SSRIs and other CNS agents. Competitors in this space include companies developing ketamine derivatives, other glutamate modulators, and psychedelic-assisted therapies.
Industry Context
Naurex Inc. operates in CNS therapeutics development.
Key facts
Founded: 2008 · Headquarters: Evanston, US · Employees: 9 · Revenue: $5.1M · Market cap: N/A